2
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Analysis of SARS-CoV-2 genome evolutionary patterns

      research-article
      1 , 2 , 1 , 2 ,
      Microbiology Spectrum
      American Society for Microbiology
      SARS-CoV-2, genome, mutation rates, selection pressure, evolution, vaccination

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          ABSTRACT

          The spread of SARS-CoV-2 virus accompanied by public availability of abundant sequence data provides a window for the determination of viral evolutionary patterns. In this study, SARS-CoV-2 genome sequences were collected from seven countries in the period January 2020–December 2022. The sequences were classified into three phases, namely, pre-vaccination, post-vaccination, and recent period. Comparison was performed between these phases based on parameters like mutation rates, selection pressure (d N/d S ratio), and transition to transversion ratios (T i/T v). Similar comparisons were performed among SARS-CoV-2 variants. Statistical significance was tested using Graphpad unpaired t-test. The analysis showed an increase in the percent genomic mutation rates post-vaccination and in recent periods across all countries from the pre-vaccination sequences. Mutation rates were highest in NSP3, S, N, and NSP12b before and increased further after vaccination. NSP4 showed the largest change in mutation rates after vaccination. The d N/d S ratios showed purifying selection that shifted toward neutral selection after vaccination. N, ORF8, ORF3a, and ORF10 were under highest positive selection before vaccination. Shift toward neutral selection was driven by E, NSP3, and ORF7a in the after vaccination set. In recent sequences, the largest d N/d S change was observed in E, NSP1, and NSP13. The T i/T v ratios decreased with time. C→U and G→U were the most frequent transitions and transversions. However, U→G was the most frequent transversion in recent period. The Omicron variant had the highest genomic mutation rates, while Delta showed the highest d N/d S ratio. Protein-wise d N/d S ratio was also seen to vary across the different variants.

          IMPORTANCE

          To the best of our knowledge, there exists no other large-scale study of the genomic and protein-wise mutation patterns during the time course of evolution in different countries. Analyzing the SARS-CoV-2 evolutionary patterns in view of the varying spatial, temporal, and biological signals is important for diagnostics, therapeutics, and pharmacovigilance of SARS-CoV-2.

          Related collections

          Most cited references133

          • Record: found
          • Abstract: found
          • Article: not found

          Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

          A new and highly pathogenic coronavirus (severe acute respiratory syndrome coronavirus-2, SARS-CoV-2) caused an outbreak in Wuhan city, Hubei province, China, starting from December 2019 that quickly spread nationwide and to other countries around the world1-3. Here, to better understand the initial step of infection at an atomic level, we determined the crystal structure of the receptor-binding domain (RBD) of the spike protein of SARS-CoV-2 bound to the cell receptor ACE2. The overall ACE2-binding mode of the SARS-CoV-2 RBD is nearly identical to that of the SARS-CoV RBD, which also uses ACE2 as the cell receptor4. Structural analysis identified residues in the SARS-CoV-2 RBD that are essential for ACE2 binding, the majority of which either are highly conserved or share similar side chain properties with those in the SARS-CoV RBD. Such similarity in structure and sequence strongly indicate convergent evolution between the SARS-CoV-2 and SARS-CoV RBDs for improved binding to ACE2, although SARS-CoV-2 does not cluster within SARS and SARS-related coronaviruses1-3,5. The epitopes of two SARS-CoV antibodies that target the RBD are also analysed for binding to the SARS-CoV-2 RBD, providing insights into the future identification of cross-reactive antibodies.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

            How SARS-CoV-2 binds to human cells Scientists are racing to learn the secrets of severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2), which is the cause of the pandemic disease COVID-19. The first step in viral entry is the binding of the viral trimeric spike protein to the human receptor angiotensin-converting enzyme 2 (ACE2). Yan et al. present the structure of human ACE2 in complex with a membrane protein that it chaperones, B0AT1. In the context of this complex, ACE2 is a dimer. A further structure shows how the receptor binding domain of SARS-CoV-2 interacts with ACE2 and suggests that it is possible that two trimeric spike proteins bind to an ACE2 dimer. The structures provide a basis for the development of therapeutics targeting this crucial interaction. Science, this issue p. 1444
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug-Repurposing

              SUMMARY The novel coronavirus SARS-CoV-2, the causative agent of COVID-19 respiratory disease, has infected over 2.3 million people, killed over 160,000, and caused worldwide social and economic disruption 1,2 . There are currently no antiviral drugs with proven clinical efficacy, nor are there vaccines for its prevention, and these efforts are hampered by limited knowledge of the molecular details of SARS-CoV-2 infection. To address this, we cloned, tagged and expressed 26 of the 29 SARS-CoV-2 proteins in human cells and identified the human proteins physically associated with each using affinity-purification mass spectrometry (AP-MS), identifying 332 high-confidence SARS-CoV-2-human protein-protein interactions (PPIs). Among these, we identify 66 druggable human proteins or host factors targeted by 69 compounds (29 FDA-approved drugs, 12 drugs in clinical trials, and 28 preclinical compounds). Screening a subset of these in multiple viral assays identified two sets of pharmacological agents that displayed antiviral activity: inhibitors of mRNA translation and predicted regulators of the Sigma1 and Sigma2 receptors. Further studies of these host factor targeting agents, including their combination with drugs that directly target viral enzymes, could lead to a therapeutic regimen to treat COVID-19.
                Bookmark

                Author and article information

                Contributors
                Role: Data curationRole: Formal analysisRole: ValidationRole: Writing – original draft
                Role: Data curationRole: MethodologyRole: SoftwareRole: ValidationRole: Visualization
                Role: ConceptualizationRole: SupervisionRole: Writing – review and editing
                Role: Editor
                Journal
                Microbiol Spectr
                Microbiol Spectr
                spectrum
                Microbiology Spectrum
                American Society for Microbiology (1752 N St., N.W., Washington, DC )
                2165-0497
                February 2024
                10 January 2024
                10 January 2024
                : 12
                : 2
                : e02654-23
                Affiliations
                [1 ]Department of Biological Sciences and Engineering, Computational and Structural Biology Laboratory, Netaji Subhas University of Technology; , Dwarka, New Delhi, India
                [2 ]Division of Biotechnology, Computational and Structural Biology Laboratory, Netaji Subhas Institute of Technology; , Dwarka, New Delhi, India
                University of Nevada Reno; , Reno, Nevada, USA
                Author notes
                Address correspondence to Sonika Bhatnagar, sbhatnagar@ 123456nsut.ac.in

                The authors declare no conflict of interest.

                Author information
                https://orcid.org/0000-0001-6349-806X
                https://orcid.org/0000-0002-8818-4240
                Article
                02654-23 spectrum.02654-23
                10.1128/spectrum.02654-23
                10846092
                38197644
                078180c2-8f9c-4394-842f-009024d7a021
                Copyright © 2024 Gupta et al.

                This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.

                History
                : 26 June 2023
                : 20 November 2023
                Page count
                supplementary-material: 0, authors: 3, Figures: 2, Tables: 8, Equations: 4, References: 136, Pages: 23, Words: 15036
                Funding
                Funded by: Indian Council of Medical Research (ICMR);
                Award ID: BMI/12(44)/2021
                Award Recipient :
                Categories
                Research Article
                virology, Virology
                Custom metadata
                February 2024

                sars-cov-2,genome,mutation rates,selection pressure,evolution,vaccination

                Comments

                Comment on this article